TMS for Parkinson's (NCT07554833)
Improve movement and thinking together
- Trial ID
- NCT07554833
- Official Title
- Clinical Effects of Accelerated rTMS Targeting Motor Cortex on Motor and Cognitive Function in Parkinson's Disease: A Prospective Pilot Study
- Goal
- Improve movement and thinking together
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- San Francisco Neurology and Sleep Center
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson s Disease
- Interventions
- TMS
Summary For Families
Goal: to see whether an accelerated course of repetitive transcranial magnetic stimulation (rTMS), aimed at the brain area that controls movement, can improve both movement and thinking in people with mild to moderate Parkinson's disease. Approach: participants get six sessions of high-frequency magnetic pulses to the motor cortex on both sides using the EXOMIND device, given twice a week over about three weeks, with motor and thinking tests before treatment and again at 1 and 3 months afterward. Eligibility: 40 people aged 50 to 90 with mild to moderate Parkinson's (stage 1, 3), who have noticeable motor symptoms and are on stable Parkinson's medications, are being enrolled; people with magnetic or electronic implants near the head, recent seizures, prior deep brain stimulation, or other safety risks are excluded.
Locations
- San Francisco Neurology and Sleep Center, San Francisco, California, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying TMS. Goal: to see whether an accelerated course of repetitive transcranial magnetic stimulation (rTMS), aimed at the brain area that controls movement, can improve both movement and thinking in people with mild to moderate Parkinson's disease. Approach: participants get six sessions of high-frequency magnetic pulses to the motor cortex on both sides using the EXOMIND device, given twice a week over about three weeks, with motor and thinking tests before treatment and again at 1 and 3 months afterward. Eligibility: 40 people aged 50 to 90 with mild to moderate Parkinson's (stage 1, 3), who have noticeable motor symptoms and are on stable Parkinson's medications, are being enrolled; people with magnetic or electronic implants near the head, recent seizures, prior deep brain stimulation, or other safety risks are excluded.
- Who can participate?
- Participants must be between 50 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 5 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- Participants receive 6 rTMS sessions, administered twice per week over approximately 3 weeks.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Questionnaires & surveys (non-invasive); Thinking & memory tests (non-invasive). Confirm the full schedule with the study coordinator.